Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial

MLA

Nir Shlomo, et al. “Bezafibrate for the Treatment of Dyslipidemia in Patients with Coronary Artery Disease: 20-Year Mortality Follow-up of the BIP Randomized Control Trial.” Cardiovascular Diabetology, vol. 15, no. 1. EBSCOhost, https://doi.org/10.1186/s12933-016-0332-6. Accessed 14 Dec. 2024.

APA

Nir Shlomo, Aharon Erez, Yaron Arbel, Sagit Ben-Zekry, Alexander Tenenbaum, Enrique Z. Fisman, Robert Klempfner, & Ilan Goldenberg. (n.d.). Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial. Cardiovascular Diabetology, 15(1). https://doi.org/10.1186/s12933-016-0332-6

Chicago

Nir Shlomo, Aharon Erez, Yaron Arbel, Sagit Ben-Zekry, Alexander Tenenbaum, Enrique Z. Fisman, Robert Klempfner, and Ilan Goldenberg. 2024. “Bezafibrate for the Treatment of Dyslipidemia in Patients with Coronary Artery Disease: 20-Year Mortality Follow-up of the BIP Randomized Control Trial.” Cardiovascular Diabetology 15 (1). Accessed December 14. doi:10.1186/s12933-016-0332-6.